ClinicalTrials.gg
CompletedNCT04827901Updated Nov 6, 2026Results posted

XEN1101 for Major Depressive Disorder

A Phase 2 interventional study of XEN1101 and Placebo in Major Depressive Disorder, sponsored by James Murrough. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by James Murrough · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
702nd of 1,323
60 · median 70
Started
2021
with 71 others
Phase 2
271 of 1,500
45 open now
Registered
1,118th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 702nd largest by enrollment of the 1,323 interventional ones that give a count, is one of 72 that started in 2021, is one of 271 in phase 2, and was the 1,118th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

211 more — sign in →

All 216 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • depression
  • anhedonia
  • major depressive disorder
  • investigational medication
  • potassium channel
  • KCNQ
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written (and assent when applicable) obtained from subject
  2. Ability for subject to comply with the requirements of the study as determined by the PI;
  3. Men and women, age 18-65 years;
  4. Participants must meet criteria for current depressive disorder (major depressive disorder [MDD]) in a major depressive episode (MDE) as determined by a study psychiatrist and confirmed using the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV);
  5. anhedonia as determined by a SHAPS score ≥ 20 at screening;
  6. Current illness severity is at least moderate, defined as a score of ≥4 on the CGI-S Scale;
  7. If female of , must agree to use of a medically accepted form of , or else agree to abstinence until 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria

  1. A primary psychiatric diagnosis other than MDD as defined by ;
  2. Has a history of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features, or bipolar I or II disorder.
  3. History of non-response to >4 adequate antidepressant trials in the current episode as determined by the Antidepressant Treatment Response Questionnaire (ATRQ);
  4. History of non-response to electroconvulsive therapy in the current depressive episode;
  5. A current diagnosis of depression with peripartum onset;
  6. Diagnosis of a major neurocognitive disorder;
  7. Meets criteria for a substance use disorder within the past 6 months, with the exception of nicotine use disorder;
  8. Patient shows signs of retinal macular disease, or retinal pigment epithelium abnormality prior to randomization.
  9. Male patients, if heterosexually active with partner who is female of , pregnant, or breastfeeding, who are unwilling to agree to barrier for the treatment period and for at least 6 months after the last dose of study drug. Female partners of male participants who are unwilling to use at least one form of highly effective contraception starting at least one cycle prior to male patient study drug initiation until 6 months after the last dose of study drug.
  10. Female participants who are pregnant, breastfeeding, or may become pregnant, or unwilling to practice birth control during participation in the study or the 6 months following;
  11. Inability to swallow capsules;
  12. Any to MRI including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more;
  13. Positive urine toxicology screen for drugs of abuse at the time of screening*;
  14. Use of any dis-allowed medication according to the study protocol**;
  15. Serious and imminent risk of self-harm or violence as determined by the PI;
  16. Extreme illness severity as defined by a CGI-S score >=6;
  17. Any current active suicidal ideation as measured by a Columbia Suicide Severity Rating Scale [C-SSRS] score of greater than 2 during the past month at the time of screening
  18. History of suicide attempt in past 2 years;
  19. Any unstable medical condition, including as follows; 19.1. History of skin or retinal pigment epithelium abnormalities caused by ezogabine; 19.2. Family history of sudden death of unknown cause; 19.3. abnormalities of laboratory tests, physical examination, or ; 19.4. History or presence of long syndrome; 19.5. QT corrected by Fridericia's formula (QTcF) > 450 msec; 19.6. Alanine transferase (; SGPT) or aspartate transferase (AST; SGOT) levels >3 times the (ULN) at screening;
  20. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    XEN1101

    Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.

    Drug: XEN1101

  • Placebo comparator
    Placebo

    Subjects will take a matching placebo daily for eight weeks.

    Drug: Placebo

Interventions

  • two 10 mg capsules

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Change in Activation Within the Reward Circuit by fMRI

    The change in activation within the bilateral ventral striatum (VS) from baseline (week 0) to end of treatment (week 8) as measured by BOLD signal with fMRI during an Incentive Flanker Task.

    Time frame: Baseline (week 0), End of treatment (week 8)

Secondary outcomes

  1. Change in Montgomery-Åsberg Depression Rating Scale Score

    The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points, higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.

    Time frame: Baseline (week 0), End of treatment (week 8)

  2. Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score

    The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms. Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).

    Time frame: Baseline (week 0), End of treatment (week 8)

  3. Change in Snaith-Hamilton Pleasure Scale (SHAPS)

    The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.

    Time frame: Baseline (week 0), End of treatment (week 8)

  4. Change in Temporal Experience of Pleasure Scale

    The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual. The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items (subscale from 10-60) and consummatory pleasure and is derived of 8 items (subscale from 8-48). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.

    Time frame: Baseline (week 0), End of treatment (week 8)

  5. Change in Clinical Global Impression Scale

    This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients". Improvement is rated on a 1-7 scale where 1 is "Very Much Improved", 2 is "Much Improved", 3 is "Minimally Improved", 4 is "No Chang"e, 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse" The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".

    Time frame: Baseline (week 0), End of treatment (week 8)

07

Results

Posted Nov 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneXEN1101Placebo
Started2931
Completed2327
Not completed64
Withdrew: Adverse event22
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up22
Withdrew: Far commute to clinical center10

Outcome measures

PrimaryChange in Activation Within the Reward Circuit by fMRI

The change in activation within the bilateral ventral striatum (VS) from baseline (week 0) to end of treatment (week 8) as measured by BOLD signal with fMRI during an Incentive Flanker Task.

Time frame:
Baseline (week 0), End of treatment (week 8)
Reported as:
Least squares mean · BOLD signal
Change in Activation Within the Reward Circuit by fMRI
BOLD signalXEN1101Placebo
Change in Activation Within the Reward Circuit by fMRI-0.11 ± 0.11-0.04 ± 0.10
SecondaryChange in Montgomery-Åsberg Depression Rating Scale Score

The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points, higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.

Time frame:
Baseline (week 0), End of treatment (week 8)
Reported as:
Least squares mean · score on a scale
Change in Montgomery-Åsberg Depression Rating Scale Score
score on a scaleXEN1101Placebo
Change in Montgomery-Åsberg Depression Rating Scale Score-13.01 ± 1.55-11.01 ± 1.50
SecondaryChange in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score

The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms. Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).

Time frame:
Baseline (week 0), End of treatment (week 8)
Reported as:
Least squares mean · score on a scale
Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score
score on a scaleXEN1101Placebo
Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score-4.79 ± 0.81-6.61 ± 0.78
SecondaryChange in Snaith-Hamilton Pleasure Scale (SHAPS)

The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.

Time frame:
Baseline (week 0), End of treatment (week 8)
Reported as:
Least squares mean · score on a scale
Change in Snaith-Hamilton Pleasure Scale (SHAPS)
score on a scaleXEN1101Placebo
Change in Snaith-Hamilton Pleasure Scale (SHAPS)-5.93 ± 1.22-4.24 ± 1.18
SecondaryChange in Temporal Experience of Pleasure Scale

The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual. The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items (subscale from 10-60) and consummatory pleasure and is derived of 8 items (subscale from 8-48). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.

Time frame:
Baseline (week 0), End of treatment (week 8)
Reported as:
Least squares mean · score on a scale
Change in Temporal Experience of Pleasure Scale
score on a scaleXEN1101Placebo
AP - Anticipatory pleasure4.61 ± 1.190.65 ± 1.15
CP - Consummatory pleasure3.05 ± 0.860.61 ± 0.83
SecondaryChange in Clinical Global Impression Scale

This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients". Improvement is rated on a 1-7 scale where 1 is "Very Much Improved", 2 is "Much Improved", 3 is "Minimally Improved", 4 is "No Chang"e, 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse" The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".

Time frame:
Baseline (week 0), End of treatment (week 8)
Reported as:
Least squares mean · score on a scale
Change in Clinical Global Impression Scale
score on a scaleXEN1101Placebo
Severity-1.31 ± 0.19-1.31 ± 0.19
Improvement-1.70 ± 0.23-1.34 ± 0.22

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XEN11010/29 (0%)1/29 (3.4%)27/29 (93.1%)
Placebo0/31 (0%)0/31 (0%)25/31 (80.6%)
Most frequent serious events
Most frequent serious events
EventXEN1101Placebo
FaintingMetabolism and nutrition disorders1/290/31
Most frequent other events
Showing 10 of 75
Most frequent other events
EventXEN1101Placebo
DizzinessNervous System Disorders11/293/31
ConfusionNervous System Disorders6/290/31
IncoordinationNervous System Disorders6/291/31
HeadacheNervous System Disorders3/295/31
FatigueGeneral Disorders4/293/31
DrowsinessNervous System Disorders4/294/31
Visual hallucinationsPsychiatric Disorders4/290/31
Blurred VisionEye Disorders3/290/31
Eye floatersEye Disorders3/290/31
Impairment of attentionNervous System Disorders3/290/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)XEN1101PlaceboTotal
Mean39.7 ± 13.236.5 ± 12.338.1 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)XEN1101PlaceboTotal
Female192140
Male101020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)XEN1101PlaceboTotal
Hispanic or Latino7815
Not Hispanic or Latino222345
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)XEN1101PlaceboTotal
American Indian or Alaska Native011
Asian549
Native Hawaiian or Other Pacific Islander000
Black or African American5712
White141428
More than one race257
Unknown or Not Reported303
08

Study locations

2 sites
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Murrough J, Fremont R, Neukam P, Govindarajulu U, Ables J, Hameed S, Corwin M, Hargrove M, Chang H, Boukezzi S, Kelly C, Swann A, Salas R, Amarneh D, Engelhardt J, Weyland A, Bagiella E, Morris L, Mathew S. A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety. Res Sq [Preprint]. 2025 Sep 15:rs.3.rs-7448148. doi: 10.21203/rs.3.rs-7448148/v1. PubMed 41001561 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication. No end date.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Any purpose. Other NDCT Database

Data sharing details ↗ · nda.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2024, 35 months.

Results were first posted in Nov 2026, 2 years 1 month after primary completion.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's 35 months is close to that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2021
First posted
Apr 1, 2021
StartActual
Oct 19, 2021
Primary completionActual
Oct 3, 2024
CompletionActual
Nov 7, 2024
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 6, 2026
Enrollment
44→60
Nov 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in activation withinActivation Within the reward circuitReward Circuit by fMRITime frame: Baseline (week 0), End of treatment (week 8)
Nov 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41001561 ↗
Nov 6, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionChange in Clinical Global Impression Scale: how it is measured was reworded
  • DescriptionChange in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score: how it is measured was reworded
  • DescriptionChange in Temporal Experience of Pleasure Scale: how it is measured was reworded
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41001561 ↗
    Enrollment 44→60
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in activation withinActivation Within the reward circuitReward Circuit by fMRITime frame: Baseline (week 0), End of treatment (week 8)
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionChange in Clinical Global Impression Scale: how it is measured was reworded
    • DescriptionChange in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score: how it is measured was reworded
    • DescriptionChange in Temporal Experience of Pleasure Scale: how it is measured was reworded
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04827901
Lead sponsor
James Murrough
Responsible party
James Murrough (Associate Professor, Psychiatry, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Apr 1, 2021
Start date
Oct 19, 2021
Primary completion
Oct 3, 2024
Completion
Nov 7, 2024
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Study contacts

James W Murrough, MD, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion